Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relap… Read more
Rigel Pharmaceuticals Inc - Asset Resilience Ratio
Rigel Pharmaceuticals Inc (RIGL) has an Asset Resilience Ratio of 22.27% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2025)
This chart shows how Rigel Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Rigel Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $114.38 Million | 22.27% |
| Total Liquid Assets | $114.38 Million | 22.27% |
Asset Resilience Insights
- Good Liquidity Position: Rigel Pharmaceuticals Inc maintains a healthy 22.27% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Rigel Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Rigel Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Rigel Pharmaceuticals Inc (2000–2025)
The table below shows the annual Asset Resilience Ratio data for Rigel Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 22.27% | $114.38 Million | $513.59 Million | +9.72pp |
| 2024-12-31 | 12.55% | $20.57 Million | $163.98 Million | -8.05pp |
| 2023-12-31 | 20.60% | $24.15 Million | $117.22 Million | -4.53pp |
| 2022-12-31 | 25.13% | $33.75 Million | $134.28 Million | -38.26pp |
| 2021-12-31 | 63.39% | $106.08 Million | $167.33 Million | +38.97pp |
| 2020-12-31 | 24.42% | $26.95 Million | $110.38 Million | -26.78pp |
| 2019-12-31 | 51.20% | $75.56 Million | $147.57 Million | +13.67pp |
| 2018-12-31 | 37.54% | $52.22 Million | $139.11 Million | -27.50pp |
| 2017-12-31 | 65.03% | $77.46 Million | $119.11 Million | -8.09pp |
| 2016-12-31 | 73.12% | $57.13 Million | $78.13 Million | +10.26pp |
| 2015-12-31 | 62.86% | $82.82 Million | $131.75 Million | -20.15pp |
| 2014-12-31 | 83.02% | $127.96 Million | $154.13 Million | -1.53pp |
| 2013-12-31 | 84.55% | $191.12 Million | $226.06 Million | -0.85pp |
| 2012-12-31 | 85.39% | $264.76 Million | $310.04 Million | -3.68pp |
| 2011-12-31 | 89.07% | $229.01 Million | $257.11 Million | -1.14pp |
| 2010-12-31 | 90.21% | $168.42 Million | $186.69 Million | +5.94pp |
| 2009-12-31 | 84.27% | $118.60 Million | $140.74 Million | +22.77pp |
| 2008-12-31 | 61.50% | $88.47 Million | $143.86 Million | +6.41pp |
| 2007-12-31 | 55.09% | $63.79 Million | $115.79 Million | +4.98pp |
| 2006-12-31 | 50.11% | $56.74 Million | $113.24 Million | +8.52pp |
| 2005-12-31 | 41.59% | $61.42 Million | $147.67 Million | -35.71pp |
| 2004-12-31 | 77.30% | $60.93 Million | $78.82 Million | +10.88pp |
| 2003-12-31 | 66.42% | $36.88 Million | $55.52 Million | +64.71pp |
| 2002-12-31 | 1.70% | $756.00K | $44.34 Million | -45.50pp |
| 2001-12-31 | 47.21% | $21.93 Million | $46.45 Million | +41.04pp |
| 2000-12-31 | 6.17% | $3.96 Million | $64.26 Million | -- |